Phio Pharmaceuticals Corp.
(NASDAQ : PHIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 10.73%61.500.0%$1907.60m
REGNRegeneron Pharmaceuticals, Inc. 5.98%612.812.5%$1175.40m
GILDGilead Sciences, Inc. 3.33%77.831.0%$1168.63m
AMGNAmgen, Inc. 2.49%229.701.3%$672.54m
VRTXVertex Pharmaceuticals, Inc. 3.81%287.961.9%$606.67m
NVAXNovavax, Inc. 2.68%46.04102.0%$590.02m
BIIBBiogen, Inc. 2.19%307.091.6%$417.42m
ILMNIllumina, Inc. -2.67%363.053.5%$387.48m
SRNESorrento Therapeutics, Inc. 2.02%5.051.8%$306.68m
ALXNAlexion Pharmaceuticals, Inc. 4.79%119.902.0%$292.13m
SGENSeattle Genetics, Inc. 3.74%157.216.1%$269.08m
AAgilent Technologies, Inc. 1.67%88.141.6%$202.48m
BMRNBioMarin Pharmaceutical, Inc. 0.90%106.554.3%$186.35m
CODXCo-Diagnostics, Inc. 3.03%18.000.0%$173.36m
INCYIncyte Corp. 1.35%101.912.5%$166.15m

Company Profile

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.